Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | MTTP | P55157 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581115 | 0.93 | TACR1 (0.45) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL1581063 | 0.92 | TACR1 (0.42) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL13899536 | 0.91 | TACR1 (0.44) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL1581148 | 0.90 | TACR1 (0.43) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL1581617 | 0.89 | KDM4E (0.49) | TACR1CASRKDM4EALDH1A1PPARA | |
| SCHEMBL1581169 | 0.89 | TACR1 (0.43) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL1581392 | 0.87 | TACR1 (0.45) | TACR1ALDH1A1SLC6A9MEN1KMT2A | |
| SCHEMBL3645560 | 0.87 | PTGDR2 (0.41) | TACR1CASRPTGDR2KDM4EALDH1A1 | |
| SCHEMBL1581363 | 0.87 | TACR1 (0.51) | TACR1MTTPSLC6A9 | |
| SCHEMBL12720550 | 0.86 | CASR (0.39) | TACR1CASRPTGDR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121579-B1 | MALONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | US | disclosed |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | US | disclosed |
| WO-2008110488-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, MTNR1B | TACR1 57/4885CASR 618/4885PTGDR2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.